Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03371979
Recruitment Status : Active, not recruiting
First Posted : December 13, 2017
Last Update Posted : November 19, 2019
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Aeglea Biotherapeutics

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2020